A prospective, multicenter, randomized, double blind study to compare the efficacy and safety of ENZ110 (similar biologic of Romiplostim) versus innovator Romiplostim in patients with chronic immune thrombocytopenia (ITP)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Romiplostim (Primary)
Indications Idiopathic thrombocytopenic purpura
Focus Registrational; Therapeutic Use
Sponsors Enzene Biosciences

Most Recent Events

20 Aug 2021 According to an Enzene Biosciences Limited media release, company received Marketing Authorization (MA) from the Drug Controller General of India (DCGI) for Romiplostim, indicated for the treatment of chronic Immune Thrombocytopenic Purpura (ITP) in adults.
19 May 2020 Status changed from recruiting to active, no longer recruiting.
27 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight